Document is current
Any future updates will be listed below
-
Authors
Notarnicola, Antonella http://orcid.org/0000-0003-0272-2931
Preger, Charlotta
Lundström, Susanna L.
Renard, Nuria
Wigren, Edvard
Van Gompel, Eveline
Galindo-Feria, Angeles S.
Persson, Helena
Fathi, Maryam
Grunewald, Johan
Jakobsson, Per-Johan
Gräslund, Susanne
Lundberg, Ingrid E.
Fernandes-Cerqueira, Cátia
-
Funding
Funding for this research was provided by:
association française contre les myopathies
reumatikerförbundet
karolinska institutet
ulla och gustaf af ugglas stiftelse
hjärt-lungfonden
stiftelsen konung gustaf v:s 80-årsfond
konung gustaf v:s och drottning victorias frimurarestiftelse
stockholms läns landsting
eu/efpia/oicr/mcgill/kth/diamond innovative medicines initiative 2 joint undertaking (875510))
eu/efpia innovative medicines initiative joint undertaking (115766)
swedish research council (2016-01254)
funds at the karolinska institutet (kid) and region stockholm
- License Information
-
More Information
Article History
Received: 1 July 2021
Accepted: 13 February 2022
First Online: 2 March 2022
Change Date: 21 July 2022
Change Type: Update
Change Details: Funding note has been added.
Declarations
:
: This study was approved by the Ethics Committee at Karolinska Institutet, Sweden. All patients gave written informed consent.
: All authors read and approved the manuscript.
: Dr. Lundberg has received a research grant from Bristol Myers Squibb and from Astra Zeneca and has served on the advisory board of Corbus Pharmaceuticals, Inc., Argenx, Kezaar, Octapharma, Orphazyme, EMD Serono Research & Development Institute, and Janssen. I Lundberg has stock shares in Roche and Novartis. The other authors declare that they have no competing interests.
